MYC and neoplasm: Omomyc, a MYC mutant that has been delivered as transgene in cell lines, and as miniprotein in preclinical tumor models, has been shown to block proliferation and induce apoptosis of cancer cells specifically, leading to immune cell infiltration [28], and might represent an attractive target for HNSCC therapy.